Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 17/20 | 0.80 |
| ▸ | DLK1 | P80370 | 2/20 | 0.80 |
| ▸ | DRG1 | Q9Y295 | 1/20 | 0.80 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.66 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.66 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.66 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.66 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.66 |
| ▸ | MAP3K10 | Q02779 | 1/20 | 0.66 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.66 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29474403 | 1.00 | MAP3K12 (0.80) | MAP3K12DLK1DRG1MAP3K13MAPK8 | |
| SCHEMBL29474404 | 1.00 | MAP3K12 (0.80) | MAP3K12DLK1DRG1MAP3K13MAPK8 | |
| SCHEMBL19821519 | 0.90 | MAP3K12 (0.67) | MAP3K12DLK1DRG1MAP3K13MAPK8 | |
| SCHEMBL19826873 | 0.89 | MAP3K12 (0.81) | MAP3K12DLK1DRG1MAP3K13MAPK8 | |
| SCHEMBL24278189 | 0.87 | MAP3K12 (0.84) | MAP3K12DLK1DRG1MAP3K13MAPK8 | |
| SCHEMBL24278046 | 0.86 | MAP3K12 (0.82) | MAP3K12DLK1DRG1MAP3K13MAPK8 | |
| SCHEMBL24278190 | 0.85 | MAP3K12 (0.81) | MAP3K12DLK1DRG1MAP3K13MAPK8 | |
| SCHEMBL29474402 | 0.84 | MAP3K12 (0.79) | MAP3K12DLK1DRG1MAP3K13MAPK8 | |
| SCHEMBL15602522 | 0.83 | MAP3K12 (0.62) | MAP3K12DLK1DRG1GPR119SYK | |
| Oxalic Acid SCHEMBL29474399 | 0.83 | MAP3K12 (0.77) | MAP3K12DLK1DRG1MAP3K13MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022051326-A1 | LZK‑TARGETING DEGRADERS AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-03-10 | — | — | WO | disclosed |